



PharmAust Expands Monepantel B Cell Lymphoma Canine Trial to the USA

- Heart of Texas (HoT) Veterinary Specialty Centre, USA joins Monepantel (MPL) pet dog B cell lymphoma trial
- Ten dogs to be treated in the USA under the FDA pilot program using MPL tablets
- New Zealand site completes treatment of first dog for a successful outcome
- 25 pet dogs recruited for the Phase 2 trial assessment to date
- PharmAust remains on track for successful Phase 2 trial endpoints
- Post-trial combination of MPL and prednisolone continues to demonstrate significant benefit to survival and quality of life

11 May 2022 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, is pleased to announce an agreement with Pathway Vet Alliance dba as Thrive Pet Healthcare and Heart of Texas (HoT) Veterinary Specialty Centre in the USA to join the MPL pet dog B cell lymphoma trial. PharmAust will send sufficient tablets for HoT to treat up to 10 dogs according to FDA pilot program guidelines.

This US expansion builds on PharmAust's new trial site in New Zealand. The New Zealand site recently completed its first 28 day treatment of a dog with B cell lymphoma for a successful trial outcome.

Trial recruitment continues in Australia with PharmAust successfully fulfilling interim Phase 2 trial endpoints. 25 pet dogs have now been treated using MPL monotherapy. With continued positive outcomes, PharmAust is preparing for a successful Phase 2 completion and the commencement of a subsequent registration trial.

In addition to the trial MPL monotherapy, eight dogs have now been treated post-trial using ongoing MPL in combination with standard of care prednisolone. This MPL and prednisolone combination has to date provided median and average survival times of approximately 140 days or 20 weeks. This compares favourably with the eight to nine week median and average survival times expected for dogs with B cell lymphoma treated with prednisolone alone. Furthermore, high qualities of life for dogs and their owners have been reported on this combination treatment.

Trial Principal Investigator Kim Agnew stated: "One aim of expanding the study sites is to accelerate the enrolment of case numbers required to enable PharmAust to close out the Phase 2 study as quickly as possible. The HoT and Pathways teams have been great to work with during the study planning phase, and we are excited to bring Monepantel for canine lymphoma to the US for the first time."

PharmAust's Chief Scientific Officer Dr Richard Mollard stated: "PharmAust is delighted to be working with the Heart of Texas Veterinary Speciality Centre to enrol pet dogs for this trial in the USA. We look forward to the successful completion of the Phase 2 trial in the near future. The combination of MPL and prednisolone post-trial to date is doubling average and medium survival times compared to prednisolone alone, enabling a greater number of trial arm options to be prepared for a registration trial".

This announcement is authorised by the Board.

Enquiries:

Dr Roger Aston
Executive Chairman
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
rmollard@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com

About PharmAust (PAA):

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$2.2 million in sales of goods & services in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

About Pathway Vet Alliance dba as Thrive Pet Healthcare

Thrive Pet Healthcare is a leading veterinary service network that uniquely delivers a continuum of care to pet families and services to veterinary hospitals. With an industry-first membership program and over 400 acute, primary, and specialty providers, Thrive Pet Healthcare offers personalized, accessible care through every stage of a pet's life and health. The veterinarian-founded and led organization provides premier benefits for practice staff while elevating privately held veterinary hospitals with innovative service and technology solutions. By focusing on the needs and aspirations of veterinary care providers, Thrive Pet Healthcare is supporting the wellbeing of the industry and raising the national bar for veterinary excellence. To learn more about Thrive Pet Healthcare, please visit <https://thrivepetcare.com/>